QurAlis

QurAlis

QurAlis is a biotechnology company developing treatments for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

May 13, 2020
QurAlis officially launches under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis (ALS) and genetically related frontotemporal dementia (FTD).

November 19, 2018
QurAlis raises a $5,500,000 seed round from BioInnovation Capital.
November 2018
QurAlis raises a $5,500,000 seed round from Viva Biotech Limited, Amgen Ventures, MP Healthcare Venture Management and BioInnovation Capital.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
QurAlis Corporation funding round, November 2018
5,500,000
November 2018
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

QurAlis Raises $5.5 Million Seed Round

BusinessWire

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
July 1, 2020
FierceBiotech
In May, startup QurAlis got a $42 million series A toward targeting the genetic causes of two rare diseases: amyotrophic lateral sclerosis and genetically related frontotemporal dementia.
Ben Adams
May 13, 2020
FierceBiotech
QurAlis has officially launched under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis and genetically related frontotemporal dementia.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.